10x Genomics (TXG) reported a Q4 net loss late Wednesday of $0.40 per diluted share, compared with a loss of $0.41 a year earlier.
Analysts polled by FactSet expected a loss of $0.30.
Revenue for the quarter ended Dec. 31 was $165 million, down from $184 million a year earlier.
Analysts surveyed by FactSet expected $159.8 million.
The company said it expects full-year 2025 revenue to be between $610 million and $630 million.
Analysts polled by FactSet expect $631 million.
Shares of the company fell about 7% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.